ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 265

Characterization of Eye Sarcoidosis with or without Systemic Involvement: Application of Iwos Criteria in an Uveitis Unit

Hiurma Sanchez-Perez1, Denisse Angel-Pereira2, Maria Garcia-Gonzalez3, Ivan Ferraz-Amaro4, Elisa Trujillo5, Maria-Jose Losada-Castilla6 and Beatriz Rodriguez Lozano7, 1Rheumatology, Rheumatology Division, Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, 2Ophtalmology, Ophtalmology Division, Hospital Universitario de Canarias, La Laguna, Spain, 3Rheumatology, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain, 4Rheumatology, Rheumatology Division, Hospital Universitario de Canarias, Tenerife, Spain, 5Rheumatology, Hospital Universitario de Canarias, La Laguna.Tenerife, Spain, 6Ophtalmology Division, Hospital Universitario de Canarias, La Laguna, Spain, 7Rheumatology, Rheumatology Department. Hospital Universitario de Canarias, S/C TENERIFE, Spain

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Diagnostic criteria, ocular involvement and sarcoidosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Miscellaneous Rheumatic and Inflammatory Diseases - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Sarcoidosis(Sa) eye involvement is the most common extrapulmonary manifestation and the initial presentation in 5-20% of cases. The definitive diagnosis is histopathological. The sensitivity(S) of the conjunctival biopsy is low,so Ocular Sa(OSa) diagnostic criteria(C.) were proposed:IWOS(First International Workshop on Ocular Sarcoidosis),with high S and specificity(1/0.95), but they have been poorly validated. Our purpose was to apply the IWOS C., to analyze their consistency with the clinical diagnosis of OSa and to asses differential features between patients with OSa and those with systemic involvement

Methods: Cross-sectional study. Clinical records from patients with presumed Sa who had been followed for 10 years in a multidisciplinar Uveitis Unit (Ophthalmology/Rheumatology) were reviewed. Clinical variables and complementary tests results were analyzed. IWOS C. were applied if OSa was suspected. Chi-square test and Kappa coefficient were used

Results: 71 patients included: 47 OSa,13 with ocular-systemic involvement (OS-Sa) and 11 with systemic involvement (SSa). Women/Men 57%/43%, mean follow-up time 9.42 years (±8.55), with no intergroup differences. Significant differences between patients with OSa vs. OS-Sa/SSa were observed: mean age at diagnosis (40.23 ±18.18 vs. 57.54 ±17.65/48.27 ±17 years,p=0.01); mean ESR(16.74 ±12.73 vs. 26.38± 15/19.4 ±31.55 mm/h, p=0.01); mean CRP(3.58 ±4.29 vs. 8.12 ±8.11/10.24 ±14.37 mg/L, p=0.03); CT abnormalities (16.6% vs. 90%/92%, p=0.001); positive biopsy(0% vs. 8/100%, p=0.002); general, joint, respiratory and skin symptoms (OSa 6-12% vs SSa 15-50%,p=0.002). ACE was increased in 74.6%, with a mean value of 71.98 ±33.59 U/L, no intergroup differences. Altered lacrimal scintigraphy was more often found in the OSa subset (26.7%) vs. OS-Sa/SSa (23.1%/0%), without statistical significance. Comparing OSa vs. OS-Sa patients, ocular involvement was as follows: anterior segment involvement 48% vs 61.5%, intermediate segment 21.3% vs. 15.4%, posterior segment 8.5% vs 0%, panuveitis 21.2% vs. 23.1%, p=0.001. If OSa,bilateral involvement was present in 60% of patients, unilateral involvement was more frecuent in OS-Sa (76%), p=0.06.There were no significant differences regarding uveitis’s presentation,course and number of crisis and specific intraocular findings. Applying IWOS Criteria and comparing OSa vs OS-Sa we can classify: Definite OSa 0% vs. 69.2%, Presumed OSa 23.4% vs. 7.7%, Probable OSa 14.9% vs. 15.4% and Possible OSa 2.1% vs. 0%; not fulfilling criteria:59.6% vs. 7.7%(p=0.001). The kappa coefficient between suspicion of OSa/OS-Sa and not fulfilling/fulfilling criteria was 0.30 (p=0.003)

Conclusion:  We could classify as Presumed vs. Probable Ocular Sarcoidosis in 25% vs. 15% of patients with suspicion but who hadn’t undergone a biopsy. We excluded the diagnosis in 60%. There wasn’t a good consistency between the suspected diagnosis/IWOS Criteria fulfillment. Ocular Sarcoidosis patients were younger and had lower ESR/CRP levels. Involvement of the anterior ocular segment was the most frequent one, bilateral in Ocular Sarcoidosis and unilateral in Ocular-Systemic Sa


Disclosure: H. Sanchez-Perez, None; D. Angel-Pereira, None; M. Garcia-Gonzalez, None; I. Ferraz-Amaro, None; E. Trujillo, None; M. J. Losada-Castilla, None; B. Rodriguez Lozano, None.

To cite this abstract in AMA style:

Sanchez-Perez H, Angel-Pereira D, Garcia-Gonzalez M, Ferraz-Amaro I, Trujillo E, Losada-Castilla MJ, Rodriguez Lozano B. Characterization of Eye Sarcoidosis with or without Systemic Involvement: Application of Iwos Criteria in an Uveitis Unit [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/characterization-of-eye-sarcoidosis-with-or-without-systemic-involvement-application-of-iwos-criteria-in-an-uveitis-unit/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterization-of-eye-sarcoidosis-with-or-without-systemic-involvement-application-of-iwos-criteria-in-an-uveitis-unit/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology